We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

Abnormal Liver Function Test Associated with Severe SARS-CoV-2 Infection

By LabMedica International staff writers
Posted on 15 Feb 2021
Print article
Image: Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection (Photo courtesy of Life Line Screening).
Image: Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection (Photo courtesy of Life Line Screening).
COVID-19 predominantly affects the pulmonary tract causing mainly respiratory symptoms, however, involvement of other organ systems has been described, including myocarditis, acute kidney injury, neurological abnormalities and acute liver injury.

During infection with SARS-CoV-2 liver injury occurs in a relevant proportion of patients. As yet, mainly elevation of aminotransferases has been described, while abnormalities of cholestatic parameters, that is, gamma-glutamyltransferase and alkaline phosphatase were reported less frequently. Liver function test (LFT) peak levels correlate with severity and/or outcome in COVID-19 patients.

Medical Scientists at the University Hospital Munich (Munich, Germany) analyzed liver function tests in a cohort of 217 patients (median age, 63 years) with SARS-CoV-2 infection and without pre-existing liver disease. Laboratory tests including liver enzymes were performed on admission and repeatedly until discharge. Values at admission as well as respective minimal and peak values were obtained via automated data extraction tools. LFT analysis included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL) and albumin. Further analyses included C-reactive protein (CRP) and interleukin 6 (IL-6). In case the patient had been transferred from another hospital, laboratory values from the initial admission were extracted from the patients’ files.

The investigators reported that abnormal LFT at hospital admission was present in 125 (58%) patients, with a predominant elevation AST; 42%, GGT; 37% and ALT; 27%, while hypoalbuminemia was observed in 33% of the patients. Of the 217 patients, 36% required treatment in the intensive care unit (ICU) and 32% underwent mechanical ventilation, with a total fatality rate of 14.7%, mostly related to COVID-19. Elevated levels of AST, ALT, GGT as well as hypoalbuminemia were also associated with an increased risk for ICU admission with odds ratio ranging from 2.06 to 13.95. On the other hand, hyperbilirubinemia, although rare at admission, was an independent risk factor for COVID-19-related death (OR, 4.80). The team noted that when hypoalbuminemia was combined with elevation of any LFT abnormality, the risk of ICU admission was markedly increased with the highest risk observed for the combination of hypoalbuminemia and AST (OR, 46.22).

The authors concluded that there was a significant correlation of elevation of baseline LFT, including GGT, as well as hypoalbuminemia with more severe courses of SARS-CoV-2 infections. Thus, baseline hypoalbuminemia when combined with other abnormal LFT in particular with abnormal AST or GGT should be regarded as a red flag indicating a more severe course of the disease and could support clinical decisions regarding closer monitoring and intensive care of patients with COVID-19. With a cut-off of 3.55 mg/dL, which is the lower limit of normal in their laboratory institute, albumin could differentiate between less and more severe cases with a sensitivity and specificity of 80%, respectively. The study was published on January 29, 2021 in the journal GUT.

Related Links:
University Hospital Munich

Gold Supplier
SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 CROM
COVID-19 Positive Control
STAT-NAT COVID-19 Positive Control
COVID-19 Anitibody Test
SGTi-flex COVID-19 IgM/IgG
New
Gold Supplier
Tumor Marker Control
Tumor Marker Control

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.